AU2020317099A1 - Selective estrogen receptor degrader - Google Patents

Selective estrogen receptor degrader Download PDF

Info

Publication number
AU2020317099A1
AU2020317099A1 AU2020317099A AU2020317099A AU2020317099A1 AU 2020317099 A1 AU2020317099 A1 AU 2020317099A1 AU 2020317099 A AU2020317099 A AU 2020317099A AU 2020317099 A AU2020317099 A AU 2020317099A AU 2020317099 A1 AU2020317099 A1 AU 2020317099A1
Authority
AU
Australia
Prior art keywords
compound
formula
cancer
less
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020317099A
Other languages
English (en)
Inventor
Jayraj Dilipbhai Aradhye
Trinadha Rao Chitturi
Ranjan Kumar Pal
Bhavesh Mohanbhai Panchal
Sandeep Pankajkumar PATHAK
Kaushik Dhanjibhai PRAJAPATI
Biswajit Samanta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Advanced Research Co Ltd
Original Assignee
Sun Pharma Advanced Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Co Ltd filed Critical Sun Pharma Advanced Research Co Ltd
Publication of AU2020317099A1 publication Critical patent/AU2020317099A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020317099A 2019-07-22 2020-07-22 Selective estrogen receptor degrader Abandoned AU2020317099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
AU2020317099A1 true AU2020317099A1 (en) 2022-02-24

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020317099A Abandoned AU2020317099A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Country Status (15)

Country Link
US (2) US11014915B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003525A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541938A (cg-RX-API-DMAC7.html)
KR (1) KR20220046586A (cg-RX-API-DMAC7.html)
CN (1) CN114302879A (cg-RX-API-DMAC7.html)
AU (1) AU2020317099A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001285A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148592A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000156A1 (cg-RX-API-DMAC7.html)
IL (1) IL290036A (cg-RX-API-DMAC7.html)
MX (1) MX2022001013A (cg-RX-API-DMAC7.html)
PE (1) PE20221588A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550182A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014386A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201157B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) * 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
US12391667B2 (en) 2019-07-22 2025-08-19 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as Autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
CN119176799B (zh) * 2024-09-19 2025-10-03 晨伫(杭州)生物科技有限责任公司 色烯衍生物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
BR112015030595A2 (pt) * 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
CN107406433A (zh) * 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
JP6768711B2 (ja) 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
US10865199B2 (en) * 2015-10-27 2020-12-15 Sun Pharma Advanced Research Company Limited Heterocyclic antiestrogens
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Also Published As

Publication number Publication date
ZA202201157B (en) 2023-07-26
JP2022541938A (ja) 2022-09-28
CA3148592A1 (en) 2021-01-28
BR112022001285A2 (pt) 2022-03-22
WO2021014386A1 (en) 2021-01-28
PE20221588A1 (es) 2022-10-10
MX2022001013A (es) 2022-02-22
US20210261534A1 (en) 2021-08-26
KR20220046586A (ko) 2022-04-14
US20210024504A1 (en) 2021-01-28
IL290036A (en) 2022-03-01
CN114302879A (zh) 2022-04-08
PH12022550182A1 (en) 2022-11-14
US11014915B2 (en) 2021-05-25
EP4003525A1 (en) 2022-06-01
CL2022000156A1 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
US11014915B2 (en) Selective estrogen receptor degrader
US20240226073A9 (en) TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
US7696357B2 (en) Stable hydrate of a muscarinic receptor antagonist
US20160354389A1 (en) Novel crystals and process of making 5-(-methyl)-2-methoxy-benzoic acid
CN1181077A (zh) 苯并吡喃类化合物及其使用方法
JP2023126540A5 (cg-RX-API-DMAC7.html)
WO2023220404A1 (en) Treatment of non-alcoholic steatohepatitis
EP2911660A1 (en) Compositions and methods for treating estrogen-related medical disorders
JP2025523065A (ja) アゾポドフィロトキシン誘導体su056のエナンチオマー
Halama et al. Improved process for the preparation of Montelukast: development of an efficient synthesis, identification of critical impurities and degradants
US20080085930A1 (en) Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
US20110200687A1 (en) Bifeprunox mesylate maintenance dose compositions and methods for using the same
US20240307349A1 (en) Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
NZ205782A (en) 3-aminopropoxyphenyl derivatives and pharmaceutical compositions
EP2275099A1 (en) Treatment of faecal incontinence with 1r,2s-methoxamine
JPWO2004031125A1 (ja) スピロ化合物、それを含有する医薬組成物及び該化合物の中間体
TWI436988B (zh) 7-〔(3-氯-6,11-二氫-6-甲基二苯并〔c,f〕〔1,2〕噻氮呯-11-基)胺〕庚酸s,s二氧化物之多晶型及其製造與使用方法
RU2855858C2 (ru) ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
EP4306115A1 (en) Pharmaceutical composition, and preparation method therefor and application thereof
WO2025255358A1 (en) Solid forms of posiphen d-tartrate and processes of preparation thereof
CN1141042A (zh) 旋光对映纯的(+)-利罗唑
WO2009142968A2 (en) Valproic acid salts
HK1141519B (en) Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
HK1124337A (en) Nuclear receptor binding agents
HK1009440B (en) Benzopyran-containing compounds and method for their use

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period